e-Edition
Obituaries
Special Sections
Special Occasions
Contact

Subscribe
Paywall Login
Login to Comment
Register

December 11th, 2017

jobs

homes

Home
News
Sports
Business
Entertainment
Classifieds
Commentary

Recent Quotes

My Watchlist

Indicators

Markets:

Overview

News

Currencies

International

Treasuries

Regeneron Pharmaceuticals (NQ:REGN)

756.73 +7.26 (+0.97%)

Streaming Delayed Price Updated: 4:00 PM EDT, Mar 26, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Regeneron Pharmaceuticals

< Previous 1 2

...

30 31 32 33 34 35 36 37 38

...

60 61 Next >

BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Acer Therapeutics Inc. (Nasdaq - ACER), Sovos Brands, Inc. (Nasdaq - SOVO), Computer Task Group, Incorporated (Nasdaq - CTG), Decibel Therapeutics, Inc. (Nasdaq -

August 31, 2023

From Brodsky & Smith LLC

Via GlobeNewswire

Looking At Regeneron Pharmaceuticals's Recent Unusual Options Activity ↗

August 30, 2023

Via Benzinga

Small Cancer Therapy Player Celularity To Provide Research Support For Regeneron's Therapy ↗

August 29, 2023

Celularity Inc (NASDAQ: CELU) shares are trading higher after the company announced a multi-year Research Collaboration Services Agreement with Regeneron Pharmaceuticals Inc (NASDAQ: REGN).

Via Benzinga

Wall Street Thinks This Tiny Biotech Company Could Soar Soon ↗

August 28, 2023

An upcoming regulatory decision could prove to be an inflection point in the biotech's life cycle.

Via The Motley Fool

Check Out What Whales Are Doing With REGN ↗

August 25, 2023

Via Benzinga

Is Regeneron Stock a Buy Now? ↗

August 25, 2023

The company's growth fuel isn't running out yet.

Via The Motley Fool

Peering Into Regeneron Pharmaceuticals's Recent Short Interest ↗

August 22, 2023

Via Benzinga

These Are the ONLY 7 Penny Stocks to Consider in August 2023 ↗

August 26, 2023

These are just a few of the most promising penny stocks to consider as we head into the final months of the year.

Via InvestorPlace

Regeneron Announces Investor Conference Presentations

August 23, 2023

From Regeneron Pharmaceuticals, Inc.

Via GlobeNewswire

Could This Medicine Be the Next Winner for Novartis? ↗

August 23, 2023

The Swiss drugmaker recently reported that a drug candidate met the primary endpoints in phase 3 clinical trials.

Via The Motley Fool

Top 5 Health Care Stocks That May Fall Off A Cliff ↗

August 23, 2023

The most overbought stocks in the health care sector presents an opportunity to go short on these overvalued companies.

Via Benzinga

Regeneron Awarded $326M Government Contract For COVID-19 Antibody Therapy Development ↗

August 22, 2023

Regeneron Pharmaceuticals Inc (NASDAQ: REGN) was awarded a government contract valued at up to $326 million on Tuesday.

Via Benzinga

18 Analysts Have This to Say About Regeneron Pharmaceuticals ↗

August 16, 2023

Via Benzinga

$100 Invested In This Stock 20 Years Ago Would Be Worth $5,400 Today ↗

August 15, 2023

Via Benzinga

This Is What Whales Are Betting On Regeneron Pharmaceuticals ↗

August 14, 2023

Via Benzinga

Regeneron Announces Agreement with BARDA Supporting Development of Next-Generation Antibody Therapy for COVID-19 Prevention

August 22, 2023

Program is part of U.S. Government’s ‘Project NextGen’ and provides partial funding for clinical development of a novel monoclonal antibody therapy

From Regeneron Pharmaceuticals, Inc.

Via GlobeNewswire

Regeneron's Crucial Eylea HD Approval: A Shield Against Potential Biosimilar Competition? ↗

August 21, 2023

Friday, the FDA approved Regeneron Pharmaceuticals Inc's (NASDAQ: REGN) approved Eylea HD (aflibercept) Injection 8 mg for wet age-related macular degeneration, diabetic macular edema,

Via Benzinga

Value Stocks Outshine Growth Amidst Rising Treasury Yields: Key Sectors and Stocks Analyzed ↗

August 21, 2023

The Vanguard Value Index Fund ETF (ARCA: VTV) has beaten the Vanguard Growth Index Fund ETF (ARCA: VUG) by 5% during the past month. The momentum shift comes as investors recalibrate their strategies...

Via Benzinga

Topics ETFs

Large Cap Biopharmaceuticals Performance 2023 YTD: Mixed Results But Lilly Is A Big Winner ↗

August 21, 2023

Biotech stocks are in a bear market since the IBB hit $177.37 in 2021 and is down 7.84% over five years.

Via Talk Markets

FDA Approves Regeneron's Drug For Ultra Rare Immune Disorder ↗

August 21, 2023

The FDA approved Regeneron Pharmaceuticals Inc's (NASDAQ: REGN) Veopoz (pozelimab-bbfg) for adult and pediatric patients one year of age and older with CHAPLE disease, known as CD55-deficient

Via Benzinga

Why This Regeneron Approval 'Could Not Come Soon Enough' As Novartis Looms ↗

August 21, 2023

The FDA signed off on Regeneron's high-dose Eylea about two months earlier than expected.

Via Investor's Business Daily

FDA Approves Regeneron Pharmaceuticals' Higher Dose Of Eylea For Age-Related Blindness ↗

August 21, 2023

The FDA approved Regeneron Pharmaceuticals Inc's (NASDAQ: REGN) approved Eylea HD (aflibercept) Injection 8 mg for wet age-related macular degeneration (wAMD), diabetic macular edema (DME),

Via Benzinga

Is Regeneron Pharmaceuticals Still a Top Growth Stock? ↗

August 21, 2023

The biotech's focus on innovation could be a boon for shareholders.

Via The Motley Fool

EYLEA HD (aflibercept) Injection 8 mg Approved by FDA for Treatment of Wet Age-related Macular Degeneration (wAMD), Diabetic Macular Edema (DME) and Diabetic Retinopathy (DR)

August 18, 2023

From Regeneron Pharmaceuticals, Inc.

Via GlobeNewswire

Veopoz™ (pozelimab-bbfg) Receives FDA Approval as the First Treatment for Children and Adults with CHAPLE Disease

August 18, 2023

From Regeneron Pharmaceuticals, Inc.

Via GlobeNewswire

Odronextamab Receives EMA Filing Acceptance for Treatment of Relapsed/Refractory Follicular Lymphoma and Diffuse Large B-cell Lymphoma

August 17, 2023

From Regeneron Pharmaceuticals, Inc.

Via GlobeNewswire

3 Strong Biotech Performers To Watch As Sector Nears Breakout

August 17, 2023

As the IBB ETF nears a potential breakout, watch for strong performers like Regeneron Pharmaceuticals, Vertex, and Exelixis to continue outperforming.

Via MarketBeat

Topics ETFs

BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: ElectraMeccanica (Nasdaq - SOLO), Computer Task Group, Incorporated (Nasdaq - CTG), Decibel Therapeutics, Inc. (Nasdaq - DBTX)

August 15, 2023

From Brodsky & Smith LLC

Via GlobeNewswire

Top Biotech Roivant, Formed By Vivek Ramaswamy, Reports Steep Losses, Light Sales ↗

August 14, 2023

The company is working on a treatment for stomach diseases ulcerative colitis and Crohn's disease.

Via Investor's Business Daily

Benzinga's 'Stock Whisper' Index: 5 Stocks Investors Are Secretly Monitoring But Not Talking About Yet ↗

August 11, 2023

Investors are on the hunt for undervalued, underfollowed and emerging stocks, and retail traders have countless methods at their disposal to uncover new information. For some, this may be...

Via Benzinga

< Previous 1 2

...

30 31 32 33 34 35 36 37 38

...

60 61 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

More ways to get to us

Facebook

Twitter

YouTube

ePaper Login
Subscribe
Subscription Services
Archive

About Us

The Lethbridge Herald
Other Publications
Food For Thought

Contact
Careers

Contact the Lethbridge Herald

504 - 7th Street South
Lethbridge, AB T1J 3Z7

[P] (403) 328-4411
[F] (403)328-4536

Print Advertising: (403) 328-4410
National Advertising: (403) 380-7585
Online Advertising: (403) 380-7585
Classifieds: (403) 328-4433

Advertising
Terms and Conditions & Privacy Policy